Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
| Status: | Completed |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 50 - Any |
| Updated: | 8/8/2018 |
| Start Date: | August 23, 2017 |
| End Date: | May 11, 2018 |
Effect of Interferon Beta-1a SC 44 µg Three Times Weekly (Tiw) (Rebif) and Dimethyl Fumarate (DMF, Tecfidera) on Infections and Lymphocytes in Patients 50 Years or Older From a Single Center Chart Review
This study will be a single center, retrospective, pilot study to determine the effect of
Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total
lymphocyte counts, grade of lymphopenia, Cluster of Differentiation 4 (CD4) and Cluster of
Differentiation 8 (CD8) counts and ratios in subjects aged 50 years and above with
Relapsing-Remitting Multiple Sclerosis (RRMS).
Rebif (interferon beta-1a) and Tecfidera (dimethyl fumarate) on infections on total
lymphocyte counts, grade of lymphopenia, Cluster of Differentiation 4 (CD4) and Cluster of
Differentiation 8 (CD8) counts and ratios in subjects aged 50 years and above with
Relapsing-Remitting Multiple Sclerosis (RRMS).
Inclusion Criteria:
- RRMS subjects who have been treated with interferon beta 1a SC 44 micro-gram thrice a
week and dimethyl fumarate in inpatient or outpatient settings during the period from
January 1, 2015 to December 31, 2015.
- Subjects with at least one year of laboratory values post-index date to analyze
lymphocyte counts, and CD4 and CD8 counts. The date of first blood draw for laboratory
tests after January 1, 2015 will be defined as the subject's index date.
Exclusion Criteria:
- Subjects who have been on treatment for less than 1 year after their index date.
We found this trial at
1
site
Click here to add this to my saved trials
